Navigation Links
Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
Date:4/21/2008

VANCOUVER, April 21 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has elected to suspend enrolment in its U.S. and EU human clinical trials for its Vascular Wrap product candidate in patients undergoing surgery for hemodialysis access, pending a safety review to evaluate an imbalance of infections that have been observed between the two study groups. The U.S. and EU trials each consist of two study groups; (1) patients who received the graft/Vascular Wrap combination; and, (2) patients who received the graft alone.

At the onset of this study Angiotech established an independent Data Safety Monitoring Board (DSMB) in the U.S. to monitor any unexpected risks or safety issues. Angiotech recently submitted a safety summary of adverse events from the U.S. clinical trial to the DSMB, based upon having reached the 25% enrolment threshold in the U.S. clinical trial. Subsequent to that submission, Angiotech received a communication from the DSMB that one of the study groups had a greater incidence of implant site infection in comparison with the other study group. Angiotech is blinded to the groups and not currently aware of whether the increased rate of infection is in the patient group that received the graft/Vascular Wrap combination or in the patient group that received the graft alone. As a result of these observations, Angiotech has elected to notify physicians to suspend further enrolment in the trials, pending a full review of the potential cause of the implant site infections.

"We regard patient safety as the paramount obligation of any company in our industry, and upon further adjudication of the clinic
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
2. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
3. Angiotech announces director resignation
4. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
5. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
6. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
7. Angiotech to participate in Lehman Brothers Healthcare Conference
8. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
9. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
10. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
11. Angiotech announces results for the fourth quarter ended December 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  In recognition of ... collaborated with hemophilia advocacy groups to illuminate more than 15 ... , including Boston,s Zakim Bridge and ... New Orleans, Mercedes-Benz Superdome and ... occur during the evening of April 17, and coincide with ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... 2015 ChemRar High ... and R&D group, and Lancet, Russian Distribution ... and commercialization of new medicines in ... to stimulate the innovative development of the ... http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... April 4 /PRNewswire-FirstCall/ - ProMetic Life Sciences ... Rohwer, Pathogen,Removal and Diagnostics Technology Inc.,s ("PRDT") ... Research Scientist will present at,the American Chemical ... from April 6 - 10, 2008. Drs ...
... /Xinhua-PRNewswire-FirstCall/ -- WuXi,PharmaTech (Cayman) Inc. (NYSE: ... and medical device research and development,outsourcing company ... States, today,announced that it has filed a ... and Exchange Commission for a proposed follow-on ...
... FRANCISCO, Calif., and SINGAPORE, April 4, 2008 /PRNewswire/,-- ... on the,discovery and development of monoclonal antibody therapeutics ... today announced a,collaboration to advance the discovery of ... of the agreement, Raven will license its proprietary,whole ...
Cached Biology Technology:Prometic to present at the American Chemical Society 2Prometic to present at the American Chemical Society 3Prometic to present at the American Chemical Society 4WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering 2Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... University of Georgia researcher has invented a new ... clothing, face masks, paper towelsand yes, even diapers, ... germ-free. The simple and inexpensive anti-microbial technology ... can be applied during the manufacturing process or ...
... is available in German . , The centromere ... protein complex known as the kinetochore is assembled. During cell ... of the cytoskeleton, thereby mediating the segregation of chromosomes to ... Institute of Immunobiology and Epigenetics and BIOSS in Freiburg have ...
... Professor Michael Davies will tell the annual meeting of ... (Wednesday) that the "vanishing twin" phenomenon, in which only ... starts as a multiple pregnancy, is linked to a ... to a nearly three-fold risk of multiple malformations. ...
Cached Biology News:New UGA technology makes textiles permanently germ-free; targets health care-associated infections 2New UGA technology makes textiles permanently germ-free; targets health care-associated infections 3Kinetochores prefer the 'silent' DNA sections of the chromosome 2'Vanishing twin' explains increased risk of birth defects 2'Vanishing twin' explains increased risk of birth defects 3'Vanishing twin' explains increased risk of birth defects 4
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes as ... "driven" to completion. A protective agent for SH ... many other preparations. Blocks the lethal and hypnotic ... Contaminants: Heavy metals: ≤1 ppm. ...
... HVJ (hemagglutinating virus of Japan, also ... a tool for transfection of molecules by ... are for siRNA (RNAi), Protein, Oligo, cDNA, ... and in vivo. GenomONE-Neo EX has a ...
... ChIP-on-chip Microarray is specifically designed for ... DNA binding proteins by pairing chromatin ... This set delivers robust hybridization and ... binding events and fewer false positives. ...
... precision, more user-friendliness and absolute reliability united ... definition of the Mastercycler ep system. In ... has been developing dynamically. The same applies ... To keep pace with these technological ...
Biology Products: